The use of polymeric meshes for Pelvic Organ Prolapse: current concepts, challenges and future perspectives by Mancuso, E et al.
This is a repository copy of The use of polymeric meshes for Pelvic Organ Prolapse: 
current concepts, challenges and future perspectives.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/147644/
Version: Accepted Version
Article:
Mancuso, E orcid.org/0000-0003-1742-1656, Downey, C orcid.org/0000-0001-9818-8002, 
Doxford-Hook, E et al. (2 more authors) (2020) The use of polymeric meshes for Pelvic 
Organ Prolapse: current concepts, challenges and future perspectives. Journal of 
Biomedical Materials Research - Part B Applied Biomaterials, 108 (3). pp. 771-789. ISSN 
1552-4973 
https://doi.org/10.1002/jbm.b.34432
© 2019 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: 
Mancuso, E , Downey, C , Doxford-Hook, E et al. (2019) The use of polymeric meshes for 
Pelvic Organ Prolapse: current concepts, challenges and future perspectives. Journal of 
Biomedical Materials Research - Part B Applied Biomaterials. ISSN 1552-4973, which has 
been published in final form at https://doi.org/10.1002/jbm.b.34432. This article may be 
used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use
of Self-Archived Versions.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
The use of polymeric meshes for pelvic organ prolapse: current concepts, challenges and 
future perspectives 
Elena Mancuso1, Candice Downey2, Elizabeth Doxford-Hook3, Michael G Bryant4, Peter 
Culmer4 
1. Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, 
BT370QB, UK 
2. Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, LS29JT, UK 
3. Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD96RJ, UK 
4. School of Mechanical Engineering, University of Leeds, Leeds, LS29JT, UK 
Corresponding author email: e.mancuso@ulster.ac.uk 
 
Keywords: pelvic organ prolapse, synthetic surgical meshes, polymers, electrospun fibers, 
tissue engineering. 
Abbreviations: POP, pelvic organ prolapse; POP-Q, Pelvic Organ Prolapse Quantification; 
POPPY, Pelvic Organ Prolapse Physiotherapy; SUI, stress urinary incontinence; FDA, Food and 
Drug Administration; PP, polypropylene; PET, polyethylene terephthalate; ePTFE, expanded 
polytetrafluoroethylene; ECM, extracellular matrix; MHRA, Medicines and Healthcare 
product Regulatory Agency; NHS, National Health Service; PLA, polylactic acid; PLGA, 
poly(lactic-co-glycolic acid); PCL, polycaprolactone; PU, polyurethane; PVDF, polyvinylidene 
fluoride; PLCL, poly (L-lactide-co-caprolactone); PLGA, poly(lactic-co-glycolic acid); PLGT, 
poly(Llactide)-trimethylene carbonate-gycolide); PEO, polyethylene oxide; bFGF, basic 
fibroblast growth factor; GTGF, connective tissue growth factor; MSCs, mesenchymal stem 
cells. 
2 
 
Abstract 
Pelvic organ prolapse (POP) is one of the most common chronic disorders in women, 
impacting the quality of life of millions of them worldwide. More than 100 surgical procedures 
have been developed over the decades to treat POP. However, the failure of conservative 
strategies and the number of patients with recurrence risk have increased the need for 
further adjuvant treatments. Since their introduction, surgical synthetic meshes have 
dramatically transformed POP repair showing superior anatomic outcomes in comparison to 
traditional approaches. Although significant progress has been attained, among the meshes 
in clinical use, there is no single mesh appropriate for every surgery. Furthermore, due to the 
risk of complications including acute and chronic infection, mesh shrinkage, and erosion of 
the tissue, the benefits of the use of meshes have recently been questioned.  
The aim of this work is to review the evolution of POP surgery, analysing the current 
challenges, and detailing the key factors pertinent to the design of new mesh systems. 
Starting with a description of the pelvic floor anatomy, the paper then presents the traditional 
treatments used in pelvic organ disorders. Next, the development of synthetic meshes is 
described with an insight into how their function is dependent on both mesh design variables 
(i.e. material, structure, functional treatment) and surgical applications. These are then linked 
to common mesh-related complications, and an indication of current research aiming to 
address these issues.  
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1. Introduction 
Pelvic organ prolapse, which has been ĚĞĨŝŶĞĚĂƐ “the descent of one or more of the anterior 
vaginal wall, posterior vaginal wall, the uterus (cervix) or the apex of the vagina (vaginal vault 
or cuff scar after hysterectomy) ?[1], is one of the most common chronic disorders in women, 
affecting almost half of all women over 50 years of age [2]. The majority of women are 
asymptomatic. Of the 20% of women who present with clinically relevant symptoms [3], the 
peak incidence occurs in women aged 60-69 [4]. Symptoms usually involve one or more of 
the urinary, bowel or vaginal organs. Urinary symptoms range from urgency (the sudden, 
compelling urge to urinate) and frequency of urination to a weak stream and, ultimately, 
incontinence. Similarly, bowel symptoms range from a sensation of incomplete emptying to 
fulminant faecal incontinence. Vaginal symptoms include sexual dysfunction, pain, mucus 
discharge and bleeding [5]. 
The anatomy of the female pelvic floor has been exhaustively described in previous literature 
[6 W8]. In brief, the pelvic floor consists of three levels of support. Specifically, the complex 
architecture of the pelvic floor comprises of a heterogeneous composition of muscles and 
supporting tissue (fascia), each providing suspension, attachment or fusion (see Figure 1). 
Level one provides suspension; the cardinal and uterosacral ligaments provide semi-vertical 
support of the cervix and upper vagina. Level two is comprised of the arcus tendinous fascia 
and fascia of the pubococcygeus and iliococcygeus muscles; these provide attachment for the 
pelvic floor muscles and support the middle third of the vagina at the pelvic side wall. The 
third level is the fusion of the pelvic floor at the urogenital diaphragm and perineal body. The 
endopelvic fascia provides additional support to the structures of the pelvic floor. The fascia 
lies inferior to the abdominal peritoneum and can be found as an uninterrupted entity with 
variations in its density throughout its structure [9,10]. Pelvic organ prolapse occurs due to 
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reduction in fascia and muscle strength, resulting in descent of the pelvic organs through the 
vagina as represented in Figure 2 [11]. 
Although the etiology of POP is multifactorial, multiparity is a major risk factor. Pregnancy 
and/or vaginal delivery stretch the structural muscles in the pelvis, leading to loss of support. 
Furthermore, vaginal delivery, especially involving a large baby, a long labour, or the use of 
forceps or extractive devices may damage nerves, leading to further muscle weakness [12]. 
Other risk factors include aging and menopause. The decline in oestrogen levels at 
menopause causes loss of muscle elasticity and weakens pelvic floor support. Increased intra-
abdominal pressure due to obesity, pelvic tumours, excess straining or coughing can also 
contribute to POP disorders [3]. Hysterectomy, nerve disorders, connective tissue disorders, 
degenerative neurologic conditions and prior pelvic surgery have also been implicated in POP 
[12].  
POP is classified according to the affected anatomical pelvic compartment: anterior, apical or 
posterior. The anterior compartment includes the bladder, bladder neck, and urethra. The 
apical compartment includes the uterus (or cul-de-sac after hysterectomy). The posterior 
compartment includes the rectum and anal canal [10]. An anterior prolapse, also known as a 
cystocele, is prolapse of the anterior compartment. The bladder descends posteriorly into the 
genital hiatus toward the vaginal introitus. A posterior prolapse, or rectocele, is prolapse of 
the rectum anteriorly into the perineal body, compressing the posterior vaginal wall. An 
enterocele describes an apical prolapse where either the uterus (uterine prolapse) or the 
distal cervix (vaginal vault prolapse, in cases of previous hysterectomy) descend through the 
vaginal canal [4]. 
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Several systems exist to grade POP. These systems provide an objective, consistent measure 
to report the degree of POP, both clinically and for research purposes. The use of a 
standardized system to describe POP is a key component of treatment decisions. The most 
commonly used method is the Pelvic Organ Prolapse Quantification (POP-Q) system (see 
Table 1). This was created by the Standardization Subcommittee of the International 
Continence Society in an effort to develop an encoding tool useful to both clinicians and 
researchers. This system  relies on specific measurements of defined points in the midline of 
the vaginal wall [13]. Also, with the POP-Q system grades are assigned according to the 
amount of prolapse seen whilst the patient undertakes the Valsalva manoeuvre (forced 
exhalation against a closed glottis) in relation to a fixed reference point, the hymen [14]. 
Researchers favour this approach because specific measurements at nine sites are recorded 
in a tic Wtac Wtoe grid. Furthermore, through the use of POP WQ system interobserver 
agreement and reliability are improved in comparison to the other available systems [13]. 
2. Management of pelvic organ prolapse: conservative treatments 
The initial management of patients with pelvic organ prolapse is non-operative, and includes 
lifestyle changes, dietary advice and pelvic floor retraining with biofeedback techniques. 
Conservative measures such as pelvic floor muscle training were discussed in a 2011 review 
paper by Hagen and Stark and found to be of some benefit [15]; however, the studies were 
contradictory and, whilst urinary incontinence was improved, there was no effect on the 
sensation of pressure or dragging. The POPPY (Pelvic Organ Prolapse Physiotherapy) trial 
randomised 447 participants to receive an individualised programme of pelvic floor muscle 
training or a prolapse lifestyle advice leaflet and no muscle training. The study showed a 
reduction in prolapse symptoms with supervised pelvic floor exercises [16]. Although obesity 
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and heavy lifting initially contribute to prolapse occurrence, reversal of these risk factors does 
not lead to regression of the POP [17,18], although some symptoms may improve [19]. 
Conservative methods are employed when surgery is deemed unsuitable for the patient or at 
the patient ?Ɛ request. Topical hormone delivery systems can help relieve lower urinary tract 
symptoms and long term replaceable pessaries can re-establish the physical support [20].  
Surgery is the mainstay of treatment for pelvic organ prolapse and is indicated once 
conservative measures have failed to result in adequate symptom reduction. Nevertheless, 
the optimal operative strategy remains nebulous. To date, more than 100 techniques have 
been described [20]. There has been a lack of consensus or generally accepted guidelines on 
the best treatment of these conditions and, until recently, no prospective randomized trials 
comparing operative strategies [21].  
Traditional treatment options for women suffering POP often included hysterectomy plus 
vaginal wall repair if required. Nowadays, the choice of operation (as detailed in Table 2) 
ĚĞƉĞŶĚƐ ŽŶ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƐǇŵƉƚŽŵƐ ? ĚĞŐƌĞĞ ŽĨ ƉƌŽůĂƉƐĞ ? ďĂĐŬŐƌŽƵŶĚ  ?ŝŶĐůƵĚŝŶŐ
comorbidities) and request for sexual function.   
Whilst hysterectomies are still the mainstay of prolapse surgery, this is often supplemented 
by McCall culdoplasty, the Moschcowitz procedure or suturing of the cardinal and uterosacral 
ligaments to the vaginal vault [22]. These techniques are thought to prevent vault prolapse 
post-operatively and provide additional pelvic floor support. If vault prolapse is diagnosed 
during vaginal hysterectomy then sacrospinous fixation or uterosacral ligament suspension 
should be considered [21].  
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3. The advent of surgical meshes in POP surgery 
Many surgical options for the management of POP have been proposed over the years. Even 
though many advances have been achieved, outcomes after surgery remain far from perfect 
[23]. Particularly, the high failure rate of traditional techniques (average 30% rate of 
reoperation) [24], mainly based on the use of native tissue, encouraged clinicians to look for 
new solutions. Particularly, these aim to i) overcome the frequent unsatisfactory outcomes of 
conservative surgery (i.e. recurrence rate) ii) reduce the reoperation rate, and iii) enhance the 
durability of the surgical procedure, providing better anatomical results [25].  
The tremendous improvements of patient conditions, shown after hernia mesh implantation 
[26], supported by the knowledge and experience gained by the surgeons over the years in 
their use [27], boosted the introduction of these devices for the management of stress urinary 
incontinence (SUI) and POP. In the 1970s, for the first time gynaecologists started using 
surgical meshes intended for hernia repair for pelvic floor reconstructive surgery [24]. 
However, these meshes were free-form grafts, and the need to cut them into different 
shapes, and according to the specific procedure, was tedious and unsafe [28]. Hence, to fulfil 
the perceived desires of the clinical community, medical device manufacturing companies 
started producing mesh and mesh-based kits in different shapes and sizes [29]. Twenty years 
ago, the first mesh for the treatment of human incontinence was sanctioned (ProteGen sling). 
This mesh consisted of a woven polyester sling manufactured by Boston Scientific, and in 2002 
ƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐ ?&ŽŽĚĂŶĚƌƵŐĚŵŝŶŝƐƚƌĂƚŝŽŶ ?& )ĂƉƉƌŽǀĞĚƚŚĞĨŝƌƐƚƉƌŽƐƚŚĞƐŝƐĨŽƌWKW
treatment [30]. Since then, research on meshes for POP has grown considerably, as 
demonstrated by the graph in Figure 3, resulting from a search on Scopus ƵƐŝŶŐ “ŵĞƐŚ, pelvic, 
organ, prolapse ? as keywords. 
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Synthetic surgical meshes, which represent the main focus of this review, were developed as 
an alternative to biological grafts (autologous fascia has been the most widely employed [31]). 
This advancement was possible thanks to the benefits of the new implants; mainly these 
were: the lack of potential infectious disease transmission, the possibility to predict their 
resulting mechanical properties according to the manufacturing methods, and the benefit to 
reduce the operative risk associated with harvesting procedures [32]. Synthetic surgical 
meshes are currently available in many varieties, and usually classified depending on their: 
material type (non-absorbable, absorbable or composite), filament type (monofilament or 
multifilament), pore size, textile structure (knitted or woven), weight and mechanical 
properties.  
However, based on the outcomes from medical practice, the use of surgical meshes for the 
management of both SUI and POP is accompanied by benefits but also risks [23], which in 
some cases can lead to serious life-threating conditions, as will be discussed in the following 
paragraphs [33 W36].  
4. Synthetic meshes: materials 
Over the years, several biomaterials have been proposed for the development of supportive 
strategies to augment and reinforce pelvic floor region [37]. Likely to the materials intended 
for abdominal wall repair, the ideal biomaterial should be sterile, durable, not carcinogenic, 
but also withstand remodelling by body tissues, have minimal risk of infection and rejection, 
and ultimately be cost-effective [38 W40]. Additionally, once implanted the ideal biomaterial 
should possess adequate mechanical properties, withstand shrinkage, and be pliable and easy 
to manipulate during surgery [36,41]. However, in comparison to the abdomen, the pelvic 
floor is a more complex tissue, with an heterogeneous architecture that include muscles, 
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connective tissue and organs [42], and whose composition changes significantly according to 
several factors, such as age, pregnancy and menopause [43]. 
Whilst there is a general consensus of opinion that employed materials should best match the 
biological environment the optimal surface and mechanical properties for a mesh are still not 
full known [11, 44 W47]. The precedence for material choice in these applications is largely 
historic and need further consideration.  
Commonly used non-absorbable materials for POP surgery have been polypropylene (PP), 
polyethylene terephthalate (PET) and expanded polytetrafluoroethylene (ePTFE). Among 
these, polypropylene has remained the most widely adopted. It is an inert and biocompatible 
material that favours tissue ingrowth, with an acceptable fatigue durability, to last for many 
years of implantation in the biological environment, and sustainable tensile strength [48].  
Particularly in the last decades, there has been an increase of evidence that PP-based meshes 
are prone to form adhesion with the viscera [49], in some cases induce high inflammatory 
response [50 W52], and they increase their stiffness over time [44], causing the weakening of 
the surrounding tissue [53]. PET is a thermoplastic polymer belonging to the polyester family. 
Regarding its use within the reconstructive surgery, it was processed as multifilament mesh 
by Ethicon (Somerville, New Jersey, USA) and it has been known as Mersilene®. The adoption 
of Mersilene® meshes was further promoted by David Nichols in 1973 as the decisive 
treatment of severe recurrent stress urinary incontinence [54]. However, polyester 
prostheses were subjected to a controversial reputation during the years. Although they have 
higher cytocompatibility in comparison to PP meshes [55,56], they are associated with poor 
clinical outcomes, erosion and chronic infections. Most of the polyester multifilament meshes 
ŚĂǀĞŝŶƚĞƌƐƚŝĐĞƐŽĨůĞƐƐƚŚĂŶ ? ?ʅŵ ?ǁŚŝĐŚĂůůŽǁƐŵĂůůďĂĐƚĞƌŝĂƚŽŝŶĨŝůƚƌĂƚĞĂŶĚƉƌŽůŝĨĞƌĂƚĞ ?
leading in this way to greater infection and extrusion rates [57 W59].The introduction of 
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monofilament PP midurethral slings for SUI has led to the adoption of this material in place 
of Mersilene®. After PP, ePTFE was the second widely used material for reconstructive 
surgery. It was discovered in 1963, and in 1983 processed as a soft tissue patch (Gore-Tex) 
and used clinically as hernia repair prosthesis [60]. Contrary to PP, Gore-Tex patches 
implanted in the abdomen led to a less inflammatory response and visceral adhesion, thanks 
to its pliable multifilament structure [61]. However, Gore-Tex does not promote incorporation 
into the surrounding native tissue, and is associated with erosion and high rejection rates 
which has decreased the use of these meshes [62,63].  
Completely absorbable materials were designed in order to develop surgical meshes able to 
serve as supporting devices while degrading during the healing process [64]. Conversely to 
permanent meshes, which often resulted as ideal substrates for bacteria growth, leading to 
the risk of infection post implantation, these new designed meshes have the advantage to 
minimize the amount of material left in the body and reduce the foreign immune response 
[35,57]. Furthermore, considering their compositional properties, they can be used in 
children, without hampering the growth of new tissue, which together with chronic pain and 
restriction of physical movement were considered the most common drawbacks associated 
with the use of permanent meshes [64,65]. Among the absorbable materials developed for 
biomedical application, polylactic acid (Vicryl, Ethicon, Somerville, NJ, USA) and polyglycolic 
acid (Dexon, Davis and Geck, Danbury, CT, USA), are those most widely applied as meshes for 
incontinence and pelvic organ prolapse surgery [66].  
However, beyond the several advantages mentioned above, one drawback for absorbable 
meshes is associated with their mechanical behaviour; particularly, they tend to lose tensile 
strength once absorbed [67]. Thus, absorbable meshes are not indicated when prolonged 
tensile strength is required. Also, as evaluated in randomised trials, polyglycolic acid and 
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polyglactin 910 absorbable meshes were found to be associated with high recurrence rates in 
prolapse surgery [68]. 
5. Synthetic meshes: structural parameters 
According to the filament type, both absorbable and non-absorbable meshes can be classified 
as multifilament or monofilament, where multifilament fibers are braided or interwoven. 
Studies have found that multifilament mesh produces more fibrosis and acute inflammation 
than their monofilament counterparts, believed to arise from the increased surface area of 
~1.57 relative to monofilament fibers [69 W71]. Also, multifilament meshes are characterised 
by interstices of less than 10 µm within the filaments. These spaces allow bacteria to enter 
and proliferate, but prevent the host immune cells to pass through, thus increasing the risk 
of infection within the mesh. Furthermore, synthetic meshes can be characterized as 
macroporous or microporous [67,72]. Porosity is defined as a ratio of the void, or empty 
space, in a mesh to the area occupied by the mesh (void area in meters/total area in meters). 
The dimension of mesh pores plays a key role in determining which organisms (macrophages 
versus bacteria) can pass through the mesh; hence, this is considered the most important 
factor for improving the host response to mesh [56,73]. 
75 µm has been considered a significant value toward the design of a POP mesh, since the 
presence of pores with such dimension allows ingrowth of fibroblasts, blood vessels, and 
collagen fibers, which support the formation of fibrous connections with the surrounding 
tissue. However, meshes having interstices with dimensions below 10 µm provide a suitable 
housing for bacteria, resulting in higher infection rates. Specifically, the limited dimensions of 
such pores impede the passage of granulocytes and macrophages, which are too large to 
infiltrate the prosthesis, eliminate bacteria and thus prevent their proliferation [74,75]. 
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Within meshes for hernia repair, the role of pore size has been well characterized, particularly 
for polypropylene meshes. Larger pores have been shown to improve the mechanical integrity 
of the resulting mesh-tissue architecture, increasing both strength and collagen deposition in 
comparison to those resulting from grafts with smaller pore dimensions [55,56]. In fact, the 
use of this last class of mesh yielded mesh-tissue constructs with limited vascular growth and 
less mature collagen formation. Pore size also affects the mesh flexural rigidity. Small pores 
lead to a mesh with high flexural rigidity and a less compliant behaviour. For instance, Prolene 
and Marlex are both two monofilament synthetic meshes; however, given the larger pore 
sizes of Prolene in comparison to Marlex, Prolene is more flexible and pliable [67,76]. 
Besides the filament type, the geometrical arrangement of filaments is another aspect that 
has been linked to a synthetic ŵĂƚĞƌŝĂů ?Ɛhost response. According to the textile structure, 
POP meshes can be woven, knitted, or unwoven. Woven materials, which include plain, twill 
and satin, provide superior mechanical strength and shape memory; however, these devices 
fray when cut and, due to their increased bending stiffness, they are not able to conform to 
the complex geometries of the pelvic floor [69]. Knitted materials, manufactured by looping 
individual filament, consist of warp-knit, interlock, and circular knit. They possess flexibility, 
versatility, and high conformity to the anatomical structures, and most notably, they have a 
significantly lower number of complications in comparison to woven mesh. The unwoven 
materials are well absorbed but have the disadvantages of non-conformity and poor visibility 
[53,77,78].  
Along with these, mesh weight is another important parameter that needs to be considered 
for synthetic materials. In 1997, Amid classified synthetic mesh materials used in abdominal 
hernia repair according to their filament(s) structure, porosity and thus weight [72]: 
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Type I: lightweight macroporous monofilament mesh with pores greater than 7 µm in 
diameter. The large pores make it more flexible and easier to work with, although this allows 
not only fibroblasts but also bacteria to enter. 
Type II: monofilament microporous mesh with pores smaller than 10 µm in diameter with 
reduced elasticity in comparison to type I. The size of the pores prevents adhesions but allows 
bacteria infiltration, with the consequent higher risk of infection and the necessity for mesh 
removal.   
Type III: multifilament mesh, predominately macroporous with some microporous 
components. The large pores and small interstices allow bacteria to infiltrate but not 
macrophages; infection spread and restricted elasticity can be a problem associated to their 
use. 
Type IV: mesh with submicroscopic pore size (<1 µm). Often used for adhesion prevention in 
abdominal surgery, less in pelvic reconstructive surgery.  
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6. Synthetic meshes: biomechanical properties  
Since their inception, there has been recognition that the requirements for the mechanical 
properties of POP meshes differ significantly to the hernia meshes from which they were 
derived. Furthermore, these mechanical properties are fundamental to the success or failure 
of an implanted prosthesis. These aspects were explored in reviews of early POP meshes, 
ǁŚŝĐŚ ŝĚĞŶƚŝĨŝĞĚ ƚŚĂƚ  ‘ƚŚĞ ƉĞƌĨĞĐƚ ƉƌŽĚƵĐƚ ĚŽĞƐ ŶŽƚĞǆŝƐƚ Ăƚ ƉƌĞƐĞŶƚ ? ĂŶĚ ƚŚĂƚ ƚŚĞƌĞ ŝƐ ĂŶ
associated need for meshes exhibiting greater durability and elasticity [69]. Research has 
since helped improve our definition of mechanical factors relevant to mesh success, which 
include elastic modulus, failure load and stress transmission at the tissue-implant interface 
[66, 67]. Mazza and Ehret [79] describe the pursuit of  ?ŵĞĐŚĂŶŝĐĂů ďŝŽĐŽŵƉĂƚŝďŝůŝƚǇ ? by 
analysing the mechanical behaviour of implanted materials and associated soft tissues at 
different length scales. They demonstrate that multi-scale deformation behaviour is 
important when trying to match or tailor mesh properties to those of surrounding tissue. 
It is clear that the mechanical properties of POP mesh should be linked to those of the soft 
tissues and organs which it seeks to support. Studies have found that the biomechanical 
properties of vaginal tissue varies significantly pre and post menopause (see Table 3) [80], 
there is significant differentiation in mechanical properties between organs of the pelvic floor 
(bladder, vagina, rectum) and that tissues exhibit Mullins-ĞĨĨĞĐƚ  ‘ƐƚƌĞƐƐ ƐŽĨƚĞŶŝŶŐ ? ǁŝƚŚ
significant hysteresis effects [71]. For a more complete understanding of the environment in 
which POP meshes operate it is necessary to consider the pelvic floor as a biomechanical 
structure in its entirety. This should include the complex interaction between constituent 
organs, soft tissues and support structures [77]. This can be represented through animal 
models, although this involves significant approximations and limits the ability to represent 
different pathologies related to POP [48, 71]. An increasingly popular alternative is provided 
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through computational finite element modelling [38], which provides a potentially powerful 
tool to investigate dynamic loading and patient specific anatomy in POP [81] and to examine 
the response of different types of mesh implant [82].  
In conjunction to understanding the anatomy, studies have sought to characterise the 
mechanics of mesh implants and link these to pelvic floor biomechanics. The mechanical 
response of meshes is closely related to both material and structural composition (e.g. mono 
vs multi-filament and weave type), factors which are also tightly coupled with 
biocompatibility (e.g. pore size effects tissue integration) which could potentially complicate 
optimisation [38]. Testing of meshes in isolation reveals that they typically possess a complex 
set of mechanical characteristics including anisotropic viscoelastic behaviour, plastic 
deformation under typical load regimes [83] and flexural rigidity which varies with mesh 
orientation [45]. Nevertheless, there is no clear consensus on what constitutes an appropriate 
range of tests and biomechanical descriptors for comparing POP meshes [49, 72] but it is 
evident that the mechanical response changes significantly after implantation. This is notable 
in a reduction of stiffness and ultimate tensile strength and a permanent increase in length 
[84]. Additionally, loading and implantation can change structural parameters (e.g. pore size) 
which compromise biocompatibility of the implant [85]. 
/ƚŝƐĐůĞĂƌƚŚĂƚƚŚĞ ‘ŵĞĐŚĂŶŝĐĂůcharacteristics ? of POP mesh are critical in determining implant 
success. Design requirements emerging from recent research include a need for anisotropic 
meshes with properties tailored and matched to the contacting soft tissues at its surface, 
features which could be realised using techniques such as electrospinning [46]. Mechanical 
characteristics are also highly relevant to surgical application, and further work is required to 
improve our understanding of how meshes will respond when implanted to ensure they avoid 
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failure (e.g. mechanical biocompatibility) and remain effective in supporting the pelvic floor 
long-term [82]. 
7. Synthetic meshes: surface treatments 
As well as the exploration of novel mesh materials, coatings and surface treatments have 
been explored in an attempt to increase biocompatibility and reduce soft tissue trauma. The 
surface properties of the interfacing mesh are, without a doubt, one of the most important 
aspects of a device. To date, a variety of metal based and hydrophilic coatings technologies 
have been used to optimise the soft tissue- mesh interface from an adhesion, infection and 
trauma point of view. The use of bio-polymers such as alginate, collagen and dextran have 
been widely reported in literature and surface functionalisation methods. Synthetic polymers, 
such as poly-lactic-acid, poly-lactic-glycolic-acid and poly-vinyl-alcohol have also been mooted 
as potential materials to enhance and optimise the device/tissue interface. In a move towards 
more biosynthetic meshes, approaches such as collagen coating of polypropylene have been 
explored. Collagen-based biomaterials have been available for several decades and are 
becoming increasingly popular due to their perceived biocompatibility and low 
immunogenicity [68,86]. However, results and outcomes for collagen based implants vary 
substantially when translated from and between animal models to the actual clinical 
applications [87,88]. Cervigni et al. [89] evaluated the efficacy of collagen-coated 
polypropylene mesh in the correction of anterior vaginal prolapse. A commercially available 
porous collagen mesh was evaluated and was found to give high recurrence and exposure 
rates at one-year follow-up. This study is in contrast to that of Lo et al. [90] ǁŚĞƌĞ  ‘A 
substantially good clinical outcome ? was noted for patients receiving a similar mesh system. 
Another approach, presented by Faulk et al. [91], functionalised polypropylene mesh 
17 
 
materials with an extracellular matrix (ECM) material. ECM was isolated from porcine skin and 
converted to a hydrogel, enabling coating of the polypropylene mesh surfaces. Using a mouse 
model, they were able to mitigate foreign body response and associated fibrous connective 
tissue deposition that are common complications with these materials.  
Barski et al. [92] investigated the use of autologous whole blood plasma as a means of 
modifying mesh surfaces for enhance bio-compatibility. Here the sling was immersed in 
plasma 30 min prior to the procedure enabling absorption of the plasma onto the mesh 
surfaces. Results demonstrated that the functional outcomes and quality of life improved 
significantly in all groups. Other studies have quantified this approach further using animal 
models where improved cell adhesion was observed when compared to non-plasma treated 
surfaces [93,94].  
8. Clinical outcomes and insight into the existing challenges 
Over recent ǇĞĂƌƐ ? attention has increased on complications that can occur with the use of 
mesh to treat POP and SUI. The use of mesh for POP surgery has been the source of much 
scrutiny, including two public health notifications from the US Food and Drug Administration 
(FDA), and substantial litigation [23].  
In 2008 and 2011, the FDA expressed its concern about the high rate of mesh-related 
complications in POP surgery [95]. Specifically, the FDA reclassified these devices from class 
II, which generally includes moderate-risk devices, to class III, which generally includes high-
risk devices [96]. Furthermore, the FDA issued an order for all manufacturers to submit a 
premarket approval application to support the safety and effectiveness of surgical mesh for 
the transvaginal repair of POP. 
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Additionally, Departments of Health in both England and Scotland have undertaken work in 
this area, as have the Medicines and Healthcare products Regulatory Agency (MHRA) and the 
European Commission. A review by the National Health Service (NHS) England reported that 
collection of data on complications after POP surgery with and without mesh had been 
 ‘ŝŶƐƵĨĨŝĐŝĞŶƚ ? to date [97]. Lately, the first large-scale robust observational study of outcomes 
after surgical management of both incontinence and POP has been reported by the Lancet 
[98]. The study involved women aged 20 years or older, undergoing a first, single incontinence 
procedure or prolapse procedure between 1997 and 2016. According to the findings, mesh 
procedures for the treatment of incontinence are recommended, although longer term 
outcomes would be beneficial. In relation to POP procedures, the use of mesh is not suggested 
for primary prolapse repair. Conversely, similar effectiveness and complication rates have 
been found for vaginal and abdominal mesh procedures for vault prolapse, in comparison to 
non-mesh vaginal repair [98]. Hence, the study results do not favour as elective any vault 
repair procedure for POP. 
Whilst a number of meshes have been withdrawn from the market, following on the FDA 
multiple warnings, there are still several commercially-available and currently in use. These 
are reported and described in terms of key properties, advantages and disadvantages in Table 
4. 
The complications associated with mesh after pelvic organ prolapse surgery can be 
categorised into erosion, infection and retraction (see Table 5), and may co-exist. Mesh-
related complications can cause pain and sexual dysfunction. They have a significant impact 
ŽŶƉĂƚŝĞŶƚƐ ?ƋƵĂůŝƚǇŽĨůŝĨĞĂŶĚ the cost of their healthcare. Understanding the causes may 
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help elucidate new mesh designs and operative approaches to minimise these distressing 
complications.  
Mesh erosion: a generic term which includes mesh exposure (visualisation of the mesh, 
usually through the vaginal epithelium), extrusion (the passage of the mesh out of a tissue) 
and perforation.  Incidence of mesh erosion varies in the literature, but a large meta-analysis 
estimated the mean incidence of graft erosion at 10.3% [99]. Presenting symptoms depend 
on the organs involved.  Vaginal mesh exposure or extrusion can sometimes be managed with 
oestrogen cream, but frequently requires either partial or complete removal of the mesh. 
Intravesical or intraurethral mesh erosion necessitates removal of the mesh from the bladder 
or urethra and may require partial cystectomy, if the mesh has eroded into the bladder wall 
[100]. Erosion into bowel is rare and requires specialist management [101]. 
The type and size of the mesh used may have an effect on the rate of complications, and no 
mesh is immune to erosions [102]. Erosions may be due to a foreign-body reaction or the 
result of bacterial colonisation. Type I (monofilament, macroporous polypropylene) mesh is 
the preferred graft choice as it allows host tissue to infiltrate the implant, resulting in good 
support and low infection rate [102]. Laparoscopic or robotic approaches are associated with 
a lower rate of erosions [103], as is raising a full-thickness vaginal flap [102].  
Mesh infection: the incidence of mesh infection ranges from 0-8% in the literature [35]. 
Presenting symptoms include pain, fever, discharge and dyspareunia. Late signs are fistulae, 
discharging sinuses and osteomyelitis. Mesh infection requires total removal of the mesh and 
intravenous antibiotics [102]. A number of techniques can be used to minimise the risk of 
infection. Peri-operative antibiotics and thorough asepsis are recommended. It is thought 
that Type 1 mesh reduces the risk of infection by allowing the infiltration of host immune cells 
alongside bacterial cells, unlike microporous mesh which only permits the latter [102].  
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Mesh retraction: a certain degree of mesh contraction is normal and anticipated [104]. Many 
surgeons use large implants to account for the anticipated shrinkage over time [105]. 
Excessive mesh retraction can present with dyspareunia and incontinence due to non-
compliance of the vaginal wall, in addition to recurrence of the original pelvic organ prolapse 
[106][65]. If analgesia and oestrogen gels are insufficient, surgery is required to relieve the 
tension on the pelvic organs. Total removal of the mesh is rarely required, but steps can be 
taken to reduce the risk. Lightweight meshes with decreased polypropylene density are 
thought to induce less of a foreign-body response, improving tissue compliance and causing 
less contraction of the mesh [64].  
Chronic pain: The prevalence of chronic pain (lasting more than 6 months) after vaginal mesh 
surgery has been estimated up to 30% [107]. Pain is often associated with other complications 
such as mesh exposure or infection [108]. The management of chronic pain is dependent on 
its underlying cause. Muscle spasm can be treated with muscle relaxants and anti-
inflammatories [109]. Nerve pain can be managed with local anaesthetic injections to the 
nerve [110]. In patients where all other treatments have failed, mesh release or removal may 
be required [107]. This then poses the challenge of how to manage secondary prolapse once 
the mesh is removed; this is a complex topic beyond the scope of this work.     
Given the importance of pore size and porosity in the host response, it can be argued that 
maintaining these properties of a mesh is crucial for biocompatibility and positive patient 
outcomes. Unfortunately, the majority of current synthetic meshes have unstable geometries 
when loaded, resulting in the collapse of pores, nonplanar deformation (buckling and 
ǁƌŝŶŬůŝŶŐ )ĂŶĚŶĂƌƌŽǁŝŶŐĂƚƚŚĞŵŝĚƉŽƌƚŝŽŶŽĨƚŚĞŵĞƐŚ ?WŽŝƐƐŽŶ ?ƐĞĨĨĞĐƚ ) ?dŚƵƐ ?ĂĨƵƚƵƌĞŐŽĂů
of synthetic mesh is the development of a mesh that maintains a stable geometry with 
loading, does not experience pore collapse or narrowing, regardless of the direction in which 
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the load is applied. There are numerous ways in which this can be accomplished including 
reinforcing the mesh such that the pores remain stable (i.e. open) early after implantation or 
changing the geometry of the pores such that they remain open in response to loading. 
Finally, developing meshes from a biomaterial that does not permanently deform when 
loaded but rather returns to its original shape, is a desirable feature of future meshes. 
Regardless of the approach taken, it is believed that preventing the reduction in pore size and 
loss of porosity in response to loading will allow for adequate tissue in-growth and 
integration. This offers significant promise to reduce the risk of mesh-related complications.  
9. Future perspective 
9.1.  Research on pelvic tissue regeneration  
Despite advanced knowledge that has been gained during the last decades regarding POP 
surgical procedures, and also mesh material properties and manufacturing methods, it is 
evident that the ideal POP mesh has not been developed yet. Moreover, following numerous 
warnings released by the FDA, there remain concerns associated with the use of POP surgical 
meshes which has caused a notable decrease in the use of POP meshes worldwide [111 W113]. 
These problems present real opportunities for the application of new research from the 
biomaterials and tissue engineering field [114]. Recent literature highlights that researchers 
are exploring the capabilities of nanofiber-based scaffolds to develop meshes able to i) 
enhance tissue remodelling (promoting fibroblast ingrowth, extracellular matrix production 
and angiogenesis), ii) provide tensile support and iii) remain elastic to allow natural 
movement of vaginal tissue [68,114 W116]. 
Among the several methods currently investigated to prepare polymer-based nanofiber 
systems, electrospinning is the process most widely applied, being simple, cost-effective and 
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versatile [117]. The possibility to tailor material chemistry, surface functionality and 
biomechanical properties, together with the opportunity to load active agents, make 
electrospun scaffolds an appealing tissue engineering-based approach [118 W120]. Briefly, 
with this method, a syringe pump drives a polymeric solvent-based solution through an 
electrified orifice with an applied voltage (between 5 and  ? ?രŬs). By stretching the solubilized 
polymer, the electrostatic force induces firstly the formation of a polymeric jet, and ultimately 
(after the evaporation of the solvent) the deposition of nano- and micro-sized fibers onto a 
collection system. The choice of the most appropriate collection system (i.e. plate, disc, drum 
collector) depends on the desired design of the fibers (random, aligned and hybrid) and their 
final application [118,121].  
The underlying rationale of using nanofiber scaffolds is based on the biomimetic principle that 
electrospun fibers can emulate the sophisticated architecture of the native extracellular 
matrix. Moreover, fiber-based matrix in comparison to commercial surgical meshes have 
higher porosity, with pore size in a wider range, and fiber diameters down to the nanoscale 
[119]. These characteristics provide environmental and physical cues to cell attachment, 
growth, and proliferation making them a suitable POP strategy [122 W124].  
Furthermore, more than currently used knitted meshes, electrospun scaffolds allow the 
possibility to combine polymeric materials of either natural and synthetic origin within the 
same implant. This positively contributes to the development of meshes able to induce a 
constructive remodelling process, by achieving a wider range of degradation profiles as well 
as mechanical properties, and thus matching better the host tissue needs and regenerative 
potential [125]. Additionally, the pliability and adjustable stiffness of electrospun meshes help 
in preventing the formation of fibrous and scar-type tissue that, beyond bearing a high risk of 
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contraction, represents one of the greatest challenges of conventional knitted POP implants 
[126]. 
9.2. Electrospun nanomaterials-based meshes 
Currently, the most commonly investigated electrospun synthetic and natural polymers for 
pelvic floor tissue are polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), 
polycaprolactone (PCL), polyurethane (PU), gelatin and fibrinogen, used alone or as a 
combination [68,116]. Table 6 provides a summary of recently published works regarding 
nanofiber-based meshes intended for pelvic organ prolapse. 
Roman et al. evaluated the in vivo host response of two newly developed electrospun meshes, 
PLA and PU, in comparison to commercial PP and PVDF surgical meshes. After 90 days of 
implantation into an animal model, the PLA and PU meshes showed a superior integration 
than commercially available meshes, with no sign of inflammation (see Figure 4). Particularly, 
the PLA mesh exhibited better biomechanical properties, with higher degree of cell infiltration 
and neovascularization, in comparison to PU meshes [115]. Furthermore, for the first time, 
the short term efficacy of a co-electrospun PLCL/Fibrinogen in comparison to a PP mesh was 
evaluated in human pelvic floor. It was found that the use of either PLCL/Fibrinogen or PP 
ŵĞƐŚŝŵƉƌŽǀĞĚƉĂƚŝĞŶƚ ?ƐWKWƐǇŵƉƚŽŵƐ ?However, the electrospun mesh had no occurrence 
of erosion, foreign body sensation or dyspareunia  and demonstrated improved patient 
outcomes in terms of anterior vaginal prolapse when compared to commercial PP mesh [127]. 
Furthermore, besides their lightweight characteristics, electrospun meshes can provide a 
better interaction with the host cells and limit the shear stresses at the interface 
implant/tissue in vivo [47]. The potential of both synthetic and semi-synthetic nanofiber 
systems to prevent stress-shielding and shear stress at the implant/tissue interface has been 
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recently explored. Specifically, three different material compositions were tested: nylon, 
PCL/Gelatin and PLGA/PCL. All the electrospun meshes exhibited mechanical properties close 
to the soft pelvic tissues, and were less stiff than commercially available transvaginal synthetic 
meshes. Also, following in vitro tests using fibroblasts derived from both healthy patients and 
women with pelvic prolapse, all the materials revealed a positive response in terms of cell 
adhesion, proliferation and matrix production, showing promise for a new generation of 
ŝŵƉůĂŶƚƐĨŽƌƉĞůǀŝĐŇŽŽƌƌĞƉĂŝƌ [128]. 
In addition to the possibility of using an electrospinning process to manufacture 3D scaffolds 
with tailorable fiber design (in terms of both diameter and distribution) as well as mechanical 
properties, other studies have considered the opportunity to use electrospun meshes as a 
vehicle to deliver bioactive factors [129,130]. Over the years, a number of drugs including 
antibiotics, anticancer drugs, as well as vitamins and proteins have been investigated as 
loading agents for the development of smart electrospun tissue engineering meshes, 
particularly for skin wound healing and bone tissue engineering applications [131 W136]. 
Within the pelvic floor regeneration field, this possibility has been only partially explored and 
the number of research studies published is still limited. In 2016, the use of PLA meshes as a 
substrate for the incorporation and subsequent release of two derivatives (L-ascorbic acid 
and ascorbate-2-phosphate) of ascorbic acid has been explored. Ascorbic acid is known for 
being a potent stimulant of collagen synthesis [137,138]. In their study, Mangir et al. [139] 
found out that scaffolds containing both the derivatives showed a more hydrophilic behaviour 
and better mechanical properties in comparison to bare PLA scaffolds, which were used as 
control. Moreover, after in vitro tests, they concluded that fibroblast grown on the scaffolds 
treated with both ascorbic acid derivatives produced more collagen with respect to the 
control PLA scaffolds. Lately, the effect of 17-ɴ-estradiol releasing electrospun PU scaffolds 
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has also been investigated [140]. Estradiol is the most abundant form of circulating estrogens 
during the premenopausal years and considered the main female hormone, which is 
responsible for modulating endothelial cell migration, fibroblast proliferation, ECM 
production and neoangiogenesis [141,142]. Similarly to PLA/Ascorbic acid scaffolds, the 
presence of the releasing agent improves the mechanical properties of the implant, in terms 
of both strength and elasticity. In addition, the newly developed meshes showed superior 
biocompatibility (compared to PU scaffolds with no 17-ɴ-estradiol), which enhanced the 
proangiogenic potential of human adipose mesenchymal stem cells and improved tissue 
integration [140]. Moreover, the incorporation of different growth factors has been 
investigated in recent studies. Glindtvad et al. explored the effect of bFGF within a PCL/PEO 
mesh. Implants with and without growth factor were tested in vivo up to 24 weeks, using a 
rat abdominal wall model. Although both the mesh types performed well in vivo, the addition 
of bFGF did not represent an advantage both in the short and in the long term for the 
regeneration of new tissue [124]. Very recently, in an effort to improve the outcomes of the 
previous study, the same research group redesigned the PCL-based implant by incorporating 
GTGF and rat MSCs [143]. The new developed mesh showed better biomechanical and 
biochemical properties in comparison to the previous one. Hence, the possibility of combining 
tissue engineering and stem cells could be a new promising approach for the repair of POP.  
Following on the most recent findings, electropsun-based implants represent a very 
promising solution to the still open challenges in POP repair procedures. However, there are 
some aspects that require further consideration and understanding. Particularly, 
biomechanical studies on explanted electrospun matrices are still limited; hence, more 
evidences about the changes in biomechanical properties of electrospun biomaterials after in 
vivo implantation and in the long term are required. Moreover, as mentioned above, the 
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anatomical structure of pelvic floor is more complex and heterogeneous in comparison to 
human abdominal wall. Therefore, it is essential that the new proposed solutions will be 
tested in the clinically relevant position rather than another anatomical site, as very recent 
studies performed [115,127,143]. This in order to avoid the adverse events often associated 
with new released implants. Ultimately, as suggested by Vashaghian et al., clinical application 
should start with small patient studies with detailed follow-up to evaluate mesh safety and 
efficacy [126].  
10. Conclusion 
While the benefits of mesh implants can be life changing, so can the consequences of the 
adverse events linked with these interventions, which often aggravate the very condition they 
were intended to address (e.g. incontinence) or create new complications such as long-term 
pain. While any surgical procedure brings associated risks, the incidence of these in mesh 
implants is unacceptably high, which has led to regulatory action, product recall and 
widespread negative media coverage across the globe. In short, it is evident that current mesh 
technology is not fit for purpose.  
However, use of mesh implants for pelvic floor support is still widely practised, and with a 
paucity of alternative options it is crucial that research is translated to improve mesh 
technology. It is evident that the typical failure modes seen with current mesh (erosion, 
infection and retraction) stem from implants which neglect the complexities of pelvic floor 
physiology, biomechanics and biochemistry. Ideally, meshes should replicate the physical 
compliance of the pelvic floor and surrounding organs while supporting the dynamic loading 
and movement associated with normal function. This is highly challenging, particularly 
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considering that the physical properties of current clinically available mesh structures 
typically alter over time as result of tissue integration.  
Here we have reviewed how aspects of material, structure, porosity, biomechanics and 
surface treatment are intrinsic to mesh function and highly interrelated. For example, 
research addressing the challenge of providing compliant meshes which mimic soft tissue 
biomechanics must consider material and structure while ensuring that porosity and 
biocompatibility is not adversely affected during loading or tissue integration. Research into 
surface treatments shows real opportunities to improve mesh acceptance by promoting 
integration while minimising foreign body response and infection. However, the surface 
treatment effect is transient and it remains crucial that long-term mesh performance is 
appropriate and not overlooked.  
Although there is unlikely to be a single  ‘ƐŝůǀĞƌďƵůůĞƚ ?ƐŽůƵƚŝŽŶƚŽĂĐŚŝĞǀŝŶŐĂŶĞǆƚ-generation 
mesh for POP, research has highlighted that nanofiber meshes represents an exciting 
opportunity. The nano-scale nature of these materials affords improved biocompatibility and 
tissue integration while permitting the design of mechanically compliant structures which 
retain their properties after tissue integration. Furthermore, the structures high surface area 
provides the ability for long-term drug delivery through surface coatings. These features 
represent the prospect of achieving a step-change in mesh performance, notably the 
minimisation of failure modes associated with current technology. However, challenges 
remain in the adoption of this research into commercially available products. Much of the 
emerging mesh technology is at an early stage of development and has yet to be tested in 
ŚƵŵĂŶƐ ?dŚĞ ‘ƉĂƚŚǁĂǇƚŽƚƌĂŶƐůĂƚŝŽŶ ?ĨŽƌƚŚŝƐƌĞƐĞĂƌĐŚǁŝůůƌĞƋƵŝre extensive clinical studies 
and work to obtain regulatory approval [144]. 
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For new POP meshes this process will be more demanding given the recent reclassification of 
meshes by the FDA and public controversies concerning adverse events. This will require 
continued interdisciplinary research, combined with close industry engagement, to exploit 
the extant knowledge in this rapidly developing field. However, it is clear that addressing 
these challenges is crucial and offers the promise to bring life-changing advances in the quality 
of life to an underserved population. 
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